Join the club for FREE to access the whole archive and other member benefits.

$95M raised by Taysha for clinical trials of four new gene therapies


Key points from article :

Taysha Gene Therapies has raised $95 million to take new gene therapies into humans.

After selling AveXis to Novartis for $8.7 billion, CEO and SVP regrouped for a new venture.

Taysha has moved quickly since disclosing the $30 million seed round in April.

Raised $95 million series B round to take its lead asset into the clinic this year.

File a further three INDs by the end of 2021 and build a commercial-scale production plant.

TSHA-101, potential treatment for GM2 gangliosidosis, set to be the first drug to enter clinic.

Delivering the gene therapy to mice via a lumbar puncture may improve symptoms.

Taysha plans to file a flurry of INDs to quickly expand its clinical pipeline.

Taysha has identified Rett syndrome prospect TSHA-102 as the next cab off the rank.

Also, INDs for SLC6A1 haploinsufficiency disorder treatment TSHA-103.

SURF1 deficiency candidate TSHA-104 are set to follow by the end of 2021.

Taysha is focused on taking the gene therapies through the clinic and onto the market.

Company has gathered support from investors to quickly lead therapies to clinic then market

Mentioned in this article:


Gene therapy company


Global medicines company for developing and producing drugs.

Company Representative

President, CEO & Founder at Taysha Gene Therapies

Company Representative

CEO, President at AveXis, Inc.


Biotechnology company

Health Organisation

University of Texas Southwestern Medical Center.